Nano-X Imaging Ltd. (NNOX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Here's Why Nanox Stock Went Up Today
Shares of medical imaging company Nano-X Imaging (NNOX 3.02%) -- commonly referred to as Nanox -- went up on Thursday after some pretty substantial news broke regarding regulatory clearance. At 10:50 a.m.
Nano-X Imaging Ltd. (NNOX) Q3 2024 Earnings Call Transcript
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q3 2024 Earnings Conference Call November 21, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Erez Meltzer - CEO Ran Daniel - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeffrey Cohen - Ladenburg Scott Henry - Alliance Global Operator Ladies and gentlemen, thank you for standing by.
Nanox to Report Third Quarter and Financial Results on November 21, 2024
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox to Participate in Upcoming Investor Conference in September 2024
PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024:
Here's Why NanoX Imaging (NNOX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for NanoX Imaging (NNOX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium
HealthCCSng V2.0 i ntroduces additional ‘ zero calcium ' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC d etection c ategory output
Nano-X Imaging Ltd. (NNOX) Q2 2024 Earnings Call Transcript
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q2 2024 Earnings Conference Call August 20, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Erez Meltzer - CEO Ran Daniel - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Scott Henry - AGP Ross Osborn - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update
Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution Management to host conference call and webcast Tuesday, August 20, 2024 at 8:30 AM ET PETAH TIKVA, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2024 and provided a business update. Recent Highlights: Generated $2.7 million in revenue in the second quarter of 2024, compared to $2.6 million in the second quarter of 2023.
3 Artificial Intelligence (AI) Stocks That Could Go Parabolic
Nanox relies on AI to better interpret patients' scans. Reducing fraud for e-commerce companies is at the core of Riskified's business.
Nanox to Report Second Quarter and Financial Results on August 20, 2024
PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024
In a study conducted by Brigham & Women's Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards' Winner
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street
Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.
